BENAROYA RESEARCH INSTITUTE
๐บ๐ธUnited States
Study on the Safety of Abatacept in Relapsing Polychondritis
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Benaroya Research Institute
- Target Recruit Count
- 4
- Registration Number
- NCT01272856
- Locations
- ๐บ๐ธ
Virginia Mason Medical Center, Seattle, Washington, United States
Kristalose as Bowel Evacuant Prior to Colonoscopy
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2011-10-06
- Lead Sponsor
- Benaroya Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT01256541
- Locations
- ๐บ๐ธ
Virginia Mason Medical Center, Seattle, Washington, United States
Pilot Study of Biomarkers for Radiation Therapy
Suspended
- Conditions
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- Benaroya Research Institute
- Target Recruit Count
- 100
- Registration Number
- NCT01050725
- Locations
- ๐บ๐ธ
Virginia Mason Medical Center, Seattle, Washington, United States
Preventing Propofol-associated Injection Pain
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Benaroya Research Institute
- Target Recruit Count
- 156
- Registration Number
- NCT00864682
- Locations
- ๐บ๐ธ
Benaroya Research Institute, Seattle, Washington, United States
Effects of Perioperative B&O Suppositories on Post-op Pain and Morphine Use After Laparoscopic Prostatectomy
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Benaroya Research Institute
- Target Recruit Count
- 135
- Registration Number
- NCT00863928
- Locations
- ๐บ๐ธ
Virginia Mason Medical Center, Seattle, Washington, United States
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
Phase 2
Completed
- Conditions
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2010-05-26
- Lead Sponsor
- Benaroya Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00761241
- Locations
- ๐บ๐ธ
Virginia Mason Medical Center, Seattle, Washington, United States
Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer
Phase 2
Terminated
- Conditions
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2011-01-20
- Lead Sponsor
- Benaroya Research Institute
- Target Recruit Count
- 6
- Registration Number
- NCT00577356
- Locations
- ๐บ๐ธ
Virginia Mason Medical Center, Seattle, Washington, United States
Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-07-07
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Benaroya Research Institute
- Target Recruit Count
- 18
- Registration Number
- NCT00349557
- Locations
- ๐บ๐ธ
Virginia Mason Medical Center, Seattle, Washington, United States
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-06-22
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- Benaroya Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00343044
- Locations
- ๐บ๐ธ
Puget Sound Oncology Consortium (PSOC), Seattle, Washington, United States
๐บ๐ธVirginia Mason Medical Center, Seattle, Washington, United States
Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- Benaroya Research Institute
- Target Recruit Count
- 29
- Registration Number
- NCT00242918
- Locations
- ๐บ๐ธ
Virginia Mason Medical Center, Seattle, Washington, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath